摘要
丹参酮是药用植物丹参(Salvia miltiorrhiza)中具有较强生物活性的脂溶性二萜醌类化合物,是目前国际上广泛认可的有效治疗心脑血管疾病的天然药物之一.本研究通过分析过表达萜类生物合成途径中的牻牛儿基牻牛儿基焦磷酸合酶(GGPPS)的转基因丹参,发现丹参酮类化合物与叶绿素具有共同的上游生物合成途径,而下游途径因组织的特异化而不同,从而生成不同的代谢产物.通过对丹参毛状根外施两个萜类生物合成途径的抑制剂Lovastatin和Fosmidomycin,在处理6周丹参酮积累达到稳定时测定丹参酮的含量,探明了丹参酮类的生物合成主要是通过质体中的MEP途径来完成,而非胞质中的MVA途径.本研究为丹参酮类的代谢生物学及合成生物学研究提供了证据和基础.
Tanshinones, a family of lipid-soluble diterpenoids found in the medicinal plant Salvia miltiorrhiza, are widely recognized for being highly effective in the treatment of cardiovascular and cerebrovascular diseases. In this study, analysis of transgenic Salvia miltiorrhiza plants overexpressing GGPPS of the terpenoid biosynthesis pathway revealed that tanshinones share a common upstream precursor biosynthesis pathway with chlorophyll but have different downstream pathways due to specialized organ distribution, leading to distinct metabolites. Moreover, by treating Salvia miltiorrhiza hairy roots with the terpenoid biosynthesis pathway inhibitors lovastatin and fosmidomycin, we show that tanshinones are mostly synthesized via the MEP pathway in plastids, rather than the cytosolic MVA pathway. This study provides evidence and clues to aid in understanding the metabolic biology and synthetic biology of tanshinones.
作者
杨悦
杨长青
王勇
杨蕾
YANG Yue YANG Chang-Qing WANG Yong YANG Lei(Shanghai Key Laboratory of Plant Functional Genomics and Resource, Plant Science Research Center, Shanghai Chenshan Botanical Garden, Shanghai 201602, China Key Laboratory of Synthetic Biology, Institute of Plant Physiology ＆ Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200032, China Key Laboratory of Plant Ecology, Northeast Forestry University, Harbin 150040, China)
出处
《中国科学：生命科学》
CSCD
北大核心
2017年第5期586-594,共9页
Scientia Sinica(Vitae)
基金
上海市绿化和市容管理局科学技术项目(批准号:G162409)资助
